Repare Therapeutics Inc.’s RPTX share price has surged by 5.60%, which has investors questioning if this is right time to sell.

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)-- Repare Therapeutics Inc. (RPTX), a clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31 ...

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2025.

CAMBRIDGE, Mass. & MONTREAL, May 01, 2025--(BUSINESS WIRE)--Repare Therapeutics Inc. ("Repare") (Nasdaq: RPTX), a leading clinical-stage precision oncology company ...

CAMBRIDGE, Mass. & MONTREAL — Repare Therapeutics Inc. (“Repare”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that it has out-licensed its discovery platforms, ...

Repare Therapeutics Inc. (Repare), a leading clinical-stage precision oncology company, announced that it has out-licensed its discovery platforms, including certain platform and programme ...

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the acceptance of two abstracts for mini-oral ...

Morningstar brands and products Company Portfolio ...

CAMBRIDGE, Mass. & MONTREAL, April 25, 2025--(BUSINESS WIRE)--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision ...

CAMBRIDGE, Mass. & MONTREAL — Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the acceptance of two abstracts ...